The prevalence of HCV RNA positivity in anti-HCV antibodies-negative hemodialysis patients in Thrace Region. Multicentral study.
HCV
HCV RNA
Hemodialysis
Journal
Germs
ISSN: 2248-2997
Titre abrégé: Germs
Pays: Romania
ID NLM: 101596099
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
06
08
2020
revised:
05
10
2020
revised:
07
01
2021
accepted:
12
01
2021
entrez:
26
4
2021
pubmed:
27
4
2021
medline:
27
4
2021
Statut:
epublish
Résumé
HCV infection in patients under hemodialysis for end stage chronic kidney disease (ESCKD) may exist despite the absence of anti-HCV antibodies. Molecular methods are widely accepted as "gold standard" techniques for the detection of viral RNA. However, the molecular methods are more expensive in comparison to conventional methods and their replacement is not cost-effective. The aim of this study was to estimate the prevalence of HCV RNA positivity in anti-HCV negative hemodialysis patients and evaluate new diagnostic methods for the detection and the monitoring of hepatitis C in ESCKD patients. The study was performed in four hospitals of Thrace region of Greece and 233 patients with no history of hepatitis C were enrolled. Measurement of anti-HCV antibodies and HCV core antigen was performed by microparticle chemiluminescence immunoassay. Molecular detection of viral RNA was performed by the real-time RT PCR. The mean age of the patients was 64.9 ± 23.3 years. HCV-Ag was positive in 2/233 patients (0.86%). Nevertheless, viral RNA was negative in those patients. The results of the present study showed that the incidence of HCV-RNA in patients with negative anti-HCV Abs, in hemodialysis patients in Thrace region of Greece was negligible (0/233).
Identifiants
pubmed: 33898341
doi: 10.18683/germs.2021.1240
pii: germs.2021.1240
pmc: PMC8057854
doi:
Types de publication
Journal Article
Langues
eng
Pagination
52-58Informations de copyright
GERMS.
Déclaration de conflit d'intérêts
Conflicts of interest: All authors – none to declare.
Références
Eur J Gastroenterol Hepatol. 2019 Jan;31(1):29-33
pubmed: 30080685
Am J Kidney Dis. 2005 Aug;46(2):290-300
pubmed: 16112048
Nephrol Dial Transplant. 1995;10(4):541-2
pubmed: 7623999
PLoS One. 2020 May 14;15(5):e0232931
pubmed: 32407423
Kidney Int Suppl (2011). 2018 Oct;8(3):91-165
pubmed: 30675443
J Hosp Infect. 2018 Apr;98(4):412-418
pubmed: 29242141
Clin Chem Lab Med. 2018 May 24;56(6):880-888
pubmed: 29702484
Medicine (Baltimore). 2016 Jan;95(3):e2431
pubmed: 26817874
J Clin Exp Hepatol. 2020 Jul-Aug;10(4):316-321
pubmed: 32655234
Nephrol Dial Transplant. 2011 Jul;26(7):2309-16
pubmed: 21097646
J Clin Virol. 2014 Sep;61(1):145-8
pubmed: 24973282
Int J Artif Organs. 2018 Mar;41(3):168-170
pubmed: 29546809
J Clin Virol. 2012 Feb;53(2):110-5
pubmed: 22177274
Antiviral Res. 2018 Feb;150:9-14
pubmed: 29217468
World J Gastroenterol. 2016 Sep 28;22(36):8094-102
pubmed: 27688651
Hepat Mon. 2013 May 30;13(6):e9147
pubmed: 24032048
Mem Inst Oswaldo Cruz. 2001 Aug;96(6):765-9
pubmed: 11562698
J Clin Virol. 2005 Sep;34(1):81-5
pubmed: 16009596
J Ayub Med Coll Abbottabad. 2018 Jul-Sep;30(3):397-400
pubmed: 30465373
J Med Virol. 1993 Jan;39(1):11-5
pubmed: 7678636
World J Hepatol. 2015 Apr 28;7(6):885-95
pubmed: 25937865
Nephrol Dial Transplant. 1998 Jul;13(7):1804-6
pubmed: 9681732
BMC Nephrol. 2018 Nov 3;19(1):304
pubmed: 30390638
J Public Health (Oxf). 2020 Feb 28;42(1):194-197
pubmed: 30165403